Skip to main content
APLS
NASDAQ Life Sciences

Biogen Tender Offer for Apellis Pharmaceuticals Successfully Completed; Merger Imminent

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
10
Price
$41.05
Mkt Cap
$5.253B
52W Low
$16.1
52W High
$41.14
52W Position info
155% above low
Off High info
at 52W high
Rel. Volume info
11× avg
Market data snapshot near publication time

APLS has more than doubled off its 52-week low of $16.1 on elevated volume (11× avg).

Summary

Biogen has successfully completed its tender offer for Apellis Pharmaceuticals, with 82.4% of shares tendered, and expects to finalize the merger today, resulting in Apellis's delisting.


Key Events · M&A and Partnerships · APLS

  • Tender Offer Completed

    Biogen's tender offer for Apellis Pharmaceuticals expired on May 13, 2026, with 82.4% of outstanding shares validly tendered and accepted for payment.

  • Merger Consummation

    All conditions for the merger have been satisfied or waived, and the acquisition is expected to be consummated today, May 14, 2026, making Apellis a wholly-owned subsidiary of Biogen.

  • Delisting and Deregistration

    Apellis shares will be delisted from the Nasdaq Global Select Market, and the company will cease its SEC reporting obligations.


Analysis · APLS · Life Sciences

This filing confirms the successful completion of Biogen's tender offer for Apellis Pharmaceuticals. With 82.4% of shares tendered, all conditions have been met, and the merger is expected to close today, May 14, 2026. This marks the final step in Apellis becoming a wholly-owned subsidiary of Biogen, leading to its delisting from Nasdaq and the cessation of its public reporting obligations.

How filings like this one have moved

In the 30 days to Aug 24, 2026, 40.6% of the 32 measured filings Wiseek scored 10 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, APLS was trading at $41.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3B. The 52-week trading range was $16.10 to $41.14. This filing was assessed with neutral market sentiment and an importance score of 10 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

APLS - Latest Insights

APLS
May 14, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $41.05
Real-time Price: $41.05 info
Change: $0 (0%) info
Market Cap: $5.253B info
APLS
May 12, 2026, 7:06 AM EDT
Filing Type: SC TO-T/A
Importance Score:
9
Price at Filing: $41.04
Real-time Price: $41.05 info
Change: +$0.0100 (+0.02%) info
Market Cap: $5.253B info
APLS
May 12, 2026, 7:00 AM EDT
Filing Type: SC 14D9/A
Importance Score:
9
Price at Filing: $41.04
Real-time Price: $41.05 info
Change: +$0.0100 (+0.02%) info
Market Cap: $5.253B info
APLS
May 07, 2026, 6:56 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.01
Real-time Price: $41.05 info
Change: +$0.040 (+0.10%) info
Market Cap: $5.253B info
APLS
May 06, 2026, 4:37 PM EDT
Filing Type: SC TO-T/A
Importance Score:
9
Price at Filing: $41.06
Real-time Price: $41.05 info
Change: -$0.010 (-0.02%) info
Market Cap: $5.253B info